PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromid
F. Muntoni(University College London), Jonathon M. Tinsley(Mary Lyon Centre at MRC Harwell), Kate Maresh(University College London), Gary Layton(University of Geneva), Shawn Harriman(Amgen (United States)), Bina Tejura(Summit (United Kingdom)), Kay E. Davies(University of Oxford), R. Rosskamp(Summit (United Kingdom)), Angela J. Russell(University of Oxford)
Cited by 9
Related Papers
Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle
|Physiological Reviews|2002|1.2k
A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets
|Nature Genetics|1995|1.1k
A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16
|Nature|1985|705